KR20190114010A - 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들 - Google Patents

주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들 Download PDF

Info

Publication number
KR20190114010A
KR20190114010A KR1020197028285A KR20197028285A KR20190114010A KR 20190114010 A KR20190114010 A KR 20190114010A KR 1020197028285 A KR1020197028285 A KR 1020197028285A KR 20197028285 A KR20197028285 A KR 20197028285A KR 20190114010 A KR20190114010 A KR 20190114010A
Authority
KR
South Korea
Prior art keywords
cream
oxymethazolin
certain embodiments
pharmaceutically acceptable
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197028285A
Other languages
English (en)
Korean (ko)
Inventor
스튜어트 디. 쉔러
크리스토퍼 포왈라
Original Assignee
어클라리스 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어클라리스 쎄라퓨틱스, 인코포레이티드 filed Critical 어클라리스 쎄라퓨틱스, 인코포레이티드
Publication of KR20190114010A publication Critical patent/KR20190114010A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
KR1020197028285A 2011-02-15 2012-02-14 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들 Withdrawn KR20190114010A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161443210P 2011-02-15 2011-02-15
US61/443,210 2011-02-15
PCT/US2012/025068 WO2012112566A1 (en) 2011-02-15 2012-02-14 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137024232A Division KR102058756B1 (ko) 2011-02-15 2012-02-14 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들

Publications (1)

Publication Number Publication Date
KR20190114010A true KR20190114010A (ko) 2019-10-08

Family

ID=45757218

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197028285A Withdrawn KR20190114010A (ko) 2011-02-15 2012-02-14 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들
KR1020137024232A Active KR102058756B1 (ko) 2011-02-15 2012-02-14 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137024232A Active KR102058756B1 (ko) 2011-02-15 2012-02-14 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들

Country Status (11)

Country Link
US (4) US20120208858A1 (cg-RX-API-DMAC7.html)
EP (2) EP2675449B1 (cg-RX-API-DMAC7.html)
JP (3) JP6225030B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190114010A (cg-RX-API-DMAC7.html)
CN (2) CN107007546A (cg-RX-API-DMAC7.html)
AU (3) AU2012217858A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013020770A2 (cg-RX-API-DMAC7.html)
CA (1) CA2827373C (cg-RX-API-DMAC7.html)
ES (2) ES2742273T3 (cg-RX-API-DMAC7.html)
RU (1) RU2648439C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012112566A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
CA2827373C (en) 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
AU2012289968B2 (en) * 2011-08-04 2014-01-16 Omeros Corporation Stable anti-inflammatory solutions for injection
IN2014CN02961A (cg-RX-API-DMAC7.html) 2011-09-20 2015-07-03 Altavista Inst De Invest Medica S A S
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
CA2899342C (en) 2013-02-01 2021-09-21 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf
CA2928962A1 (en) * 2013-10-28 2015-05-07 Astion Pharma A/S Dermatological compositions
AU2015252947B2 (en) * 2014-05-01 2020-07-09 Anterios, Inc. Demonstrable efficacy across or within patient populations
CA2951725C (en) * 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
WO2017049148A1 (en) * 2015-09-17 2017-03-23 June Jacobs Laboratiories, Llc Compositions and methods for the treatment and prevention of radiation dermatitis
US10744135B2 (en) * 2016-06-28 2020-08-18 Doris Maria HEXSEL Use of an active substance in the treatment of melasma
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EA202090763A1 (ru) * 2017-11-15 2020-08-03 Борис Славинович ФАРБЕР Фармацевтическая композиция для стимуляции деления стволовых клеток и подавления вирулентности бактерий
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
EP3860592A4 (en) * 2018-11-26 2023-04-19 Cellix Bio Private Limited OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN AND EYE DISEASES
US20220204456A1 (en) * 2019-04-30 2022-06-30 Generos Biopharma Ltd. Compound for treating autoimmune skin diseases caused by inflammation, and use thereof
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
KR102633256B1 (ko) * 2021-10-08 2024-02-05 (주)우리스마트바이오 참당귀 추출물을 이용한 피부개선용 화장품 조성물, 이를 포함한 피부개선용 화장품 및 피부개선용 화장품 제조방법
US20250114362A1 (en) * 2022-01-05 2025-04-10 Asymmetric Therapeutics, Llc Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
US20240423959A1 (en) * 2022-06-21 2024-12-26 Jjr&D, Llc Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147275A (en) 1964-09-01 Nh-cha
US8093293B2 (en) * 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
KR100898879B1 (ko) 2000-08-16 2009-05-25 돌비 레버러토리즈 라이쎈싱 코오포레이션 부수 정보에 응답하여 하나 또는 그 이상의 파라메터를변조하는 오디오 또는 비디오 지각 코딩 시스템
US6479060B1 (en) * 2001-09-04 2002-11-12 Healthpoint, Ltd. Elegant hydrogenated castor oil ointments
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US6573301B1 (en) 2002-04-23 2003-06-03 Bradley Pharmaceuticals, Inc. Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
DK1833495T3 (da) 2005-03-15 2008-06-02 Campina Nederland Holding Bv Dermatologisk anvendelse af mælkeproteiner
WO2006105450A2 (en) * 2005-03-30 2006-10-05 Revance Therapeutics, Inc. Compositions and methods for treating acne
WO2007000192A1 (en) 2005-06-29 2007-01-04 Dsm Ip Assets B.V. Topical compositions comprising nanoparticles of an isoflavone
EP1998788A4 (en) * 2006-03-01 2011-08-03 Ruey J Yu COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR
US20080031979A1 (en) * 2006-08-04 2008-02-07 Claude Saliou Use of extracts for the treatment of viral disorders
RU2310439C1 (ru) * 2006-10-05 2007-11-20 Закрытое акционерное общество Фармацевтическое научно-производственное предприятие "Ретиноиды" (ЗАО "Ретиноиды") Мазевая акарицидная композиция и способ лечения демодекоза и сопутствующих ему заболеваний
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
PT2818184T (pt) 2007-11-16 2019-01-28 Aclaris Therapeutics Inc Composições e métodos para o tratamento de púrpura
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
MX2012004890A (es) 2009-10-26 2012-09-28 Galderma Pharma Sa Metodos para tratar o prevenir eritema agudo.
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
CA2827373C (en) 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
CA2841632A1 (en) 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use

Also Published As

Publication number Publication date
EP2675449A1 (en) 2013-12-25
US20140113947A1 (en) 2014-04-24
US20200276108A1 (en) 2020-09-03
BR112013020770A2 (pt) 2019-08-27
CN103458897A (zh) 2013-12-18
CA2827373C (en) 2019-05-14
CA2827373A1 (en) 2012-08-23
JP2017066162A (ja) 2017-04-06
ES3068788T3 (en) 2026-06-02
JP2018193399A (ja) 2018-12-06
AU2017202726A1 (en) 2017-05-18
US20120208858A1 (en) 2012-08-16
AU2019203993B2 (en) 2020-05-28
ES2742273T3 (es) 2020-02-13
AU2017202726B2 (en) 2019-03-07
RU2013141845A (ru) 2015-03-27
KR20140020912A (ko) 2014-02-19
KR102058756B1 (ko) 2020-01-22
AU2012217858A1 (en) 2013-09-05
JP2014505733A (ja) 2014-03-06
EP3578178C0 (en) 2026-04-08
WO2012112566A1 (en) 2012-08-23
CN107007546A (zh) 2017-08-04
AU2019203993A1 (en) 2019-06-27
US11541000B2 (en) 2023-01-03
JP6389534B2 (ja) 2018-09-12
EP3578178B1 (en) 2026-04-08
EP2675449B1 (en) 2019-04-24
US20190167566A1 (en) 2019-06-06
EP3578178A1 (en) 2019-12-11
JP6225030B2 (ja) 2017-11-01
RU2648439C2 (ru) 2018-03-26

Similar Documents

Publication Publication Date Title
KR102058756B1 (ko) 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들
AU2018229508B2 (en) Pharmaceutical cream compositions comprising oxymetazoline
HK1192724B (en) Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
HK1192724A (en) Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
HK1190307B (en) Pharmaceutical cream compositions comprising oxymetazoline

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190926

Application number text: 1020137024232

Filing date: 20130913

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid